Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,150.14 +22.35 (+0.44%) Dow
38,873.85 +198.17 (+0.51%) Nasdaq
16,203.03 +46.70 (+0.29%) Bitcoin USD
63,569.43 -435.51 (-0.68%) CMC Crypto 200
1,372.14 +59.52 (+4.53%)
Teleflex Incorporated (TFX)
| Previous close | 198.73 |
| Open | 201.19 |
| Bid | 81.21 x 1200 |
| Ask | 0.00 x 800 |
| Day's range | 199.12 - 206.51 |
| 52-week range | 177.63 - 262.97 |
| Volume | |
| Avg. volume | 306,906 |
| Market cap | 9.562B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 32.48 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.36 (0.67%) |
| Ex-dividend date | 29 Feb 2024 |
| 1y target est | N/A |
- GlobeNewswire
Teleflex Announces Quarterly Dividend
WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2024, to shareholders of record at the close of business on May 15, 2024. Additional information about Teleflex can be obtained from the company’s website at teleflex.com. About Teleflex Incorporated Teleflex is a global provider of medical technologies
- GlobeNewswire
Teleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
WAYNE, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. First quarter financial summary Revenues of $737.8 million, up 3.8% compared to the prior year period; up 3.8% on a constant currency basisGAAP diluted EPS from continuing operations of $0.33, compared to $1.63 in the prior year periodAdjusted diluted EPS from continuing operations of $3.21, compared to $3.09 in the prior yea
- GlobeNewswire
Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) -Additional studies examine post-surgery medication use, rates of hospitalization and adverse events of standard BPH treatments -Teleflex unveils latest advancements in BPH treatment with UroLift™ 2 System with Advanced Tissue Control (ATC) designed to treat all prostate types - WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Tel
